메뉴 건너뛰기




Volumn 46, Issue 1, 2011, Pages 79-90

Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2

(15)  Iwasaki, Yoshiaki a   Tanaka, Hironori a,k,m   Ikeada, Hiroshi b   Okamoto, Ryo Ichi c   Araki, Yasuyuki c   Yabushita, Kazuhisa d   Kobashi, Haruhiko a,e   Kariyama, Kazuya f   Kawaguchi, Mitsuhiko g   Takaguchi, Kouichi h   Sakata, Tatsuro i   Ando, Masaharu j   Sakaguchi, Kohsaku a,d   Aoki, Noriaki l,m   Shiratori, Yasushi a  


Author keywords

Chronic hepatitis C; Consensus interferon; Cost effectiveness; Genotype 2; High dose induction

Indexed keywords

ALPHA2B INTERFERON; CONSENSUS INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

EID: 78651356512     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.516449     Document Type: Article
Times cited : (5)

References (46)
  • 1
    • 0035811625 scopus 로고    scopus 로고
    • Hepatitis C virus infection
    • Lauer GM, Walker BD. Hepatitis C virus infection. N EnglJ Med 2001;345:41-52.
    • (2001) N EnglJ Med , vol.345 , pp. 41-52
    • Lauer, G.M.1    Walker, B.D.2
  • 2
    • 30044432484 scopus 로고    scopus 로고
    • American Gastroenterolog-ical Association technical review on the management of hepatitis C
    • Dienstag JL, McHutchison JG. American Gastroenterolog-ical Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64.
    • (2006) Gastroenterology , vol.130 , pp. 231-64
    • Dienstag, J.L.1    McHutchison, J.G.2
  • 3
    • 0036242165 scopus 로고    scopus 로고
    • Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
    • Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
    • (2002) Gastroenterology , vol.122 , pp. 1303-13
    • Poynard, T.1    McHutchison, J.2    Manns, M.3    Trepo, C.4    Lindsay, K.5    Goodman, Z.6
  • 5
    • 10744225023 scopus 로고    scopus 로고
    • A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C
    • Fattovich G, Zagni I, Minola E, Felder M, Rovere P, Carlotto A, et al. A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J Hepatol 2003;39:843-9.
    • (2003) J Hepatol , vol.39 , pp. 843-9
    • Fattovich, G.1    Zagni, I.2    Minola, E.3    Felder, M.4    Rovere, P.5    Carlotto, A.6
  • 7
    • 0032786260 scopus 로고    scopus 로고
    • Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: Effect of baseline viral concentration. Consensus Interferon Study Group
    • Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K, et al. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group. Am J Gastroenterol 1999;94: 3583-8.
    • (1999) Am J Gastroenterol , vol.94 , pp. 3583-8
    • Jensen, D.M.1    Krawitt, E.L.2    Keeffe, E.B.3    Hollinger, F.B.4    James, S.P.5    Mullen, K.6
  • 8
    • 0030886965 scopus 로고    scopus 로고
    • Therapy of hepatitis C: Consensus interferon trials. Consensus Interferon Study Group
    • Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepa-tology 1997;26:101S-107S.
    • (1997) Hepatology , vol.26
    • Keeffe, E.B.1    Hollinger, F.B.2
  • 9
    • 17644415729 scopus 로고    scopus 로고
    • Interferon alfacon-1 and riba-virin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C
    • Sjogren MH, Sjogren R, Holtzmuller K, Winston B, Butterfield B, Drake S, et al. Interferon alfacon-1 and riba-virin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 2005;50:727-32.
    • (2005) Dig Dis Sci , vol.50 , pp. 727-32
    • Sjogren, M.H.1    Sjogren, R.2    Holtzmuller, K.3    Winston, B.4    Butterfield, B.5    Drake, S.6
  • 10
    • 20244372974 scopus 로고    scopus 로고
    • A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lym-phoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection
    • Suzuki H, Tango T. A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lym-phoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. Hepatol Res 2002;22: 1-12.
    • (2002) Hepatol Res , vol.22 , pp. 1-12
    • Suzuki, H.1    Tango, T.2
  • 12
    • 0345695221 scopus 로고    scopus 로고
    • Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Consensus Interferon Study Group
    • Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997; 26:747-54.
    • (1997) Hepatology , vol.26 , pp. 747-54
    • Tong, M.J.1    Reddy, K.R.2    Lee, W.M.3    Pockros, P.J.4    Hoefs, J.C.5    Keeffe, E.B.6
  • 13
    • 0030886964 scopus 로고    scopus 로고
    • National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C
    • National Institutes of Health Consensus Development Con-ference Panel statement: management of hepatitis C. Hepa-tology 1997;26:2S-10S.
    • (1997) Hepatology , vol.26
  • 15
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
    • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
    • (2001) Lancet , vol.358 , pp. 958-65
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3    Rustgi, V.K.4    Shiffman, M.5    Reindollar, R.6
  • 16
    • 0026563204 scopus 로고
    • Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
    • Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673-9.
    • (1992) J Gen Virol , vol.73 , pp. 673-9
    • Okamoto, H.1    Sugiyama, Y.2    Okada, S.3    Kurai, K.4    Akahane, Y.5    Sugai, Y.6
  • 18
    • 8544229103 scopus 로고    scopus 로고
    • Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group
    • Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997;113: 558-66.
    • (1997) Gastroenterology , vol.113 , pp. 558-66
    • Shiratori, Y.1    Kato, N.2    Yokosuka, O.3    Imazeki, F.4    Hashimoto, E.5    Hayashi, N.6
  • 20
    • 33845641280 scopus 로고    scopus 로고
    • Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy
    • Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006;44: 1598-1606.
    • (2006) Hepatology , vol.44 , pp. 1598-1606
    • Del Rio, R.A.1    Post, A.B.2    Singer, M.E.3
  • 21
    • 0032731788 scopus 로고    scopus 로고
    • Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C
    • Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318-24.
    • (1999) Hepatology , vol.30 , pp. 1318-24
    • Younossi, Z.M.1    Singer, M.E.2    McHutchison, J.G.3    Shermock, K.M.4
  • 22
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alpha2a and ribavirin com-bination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
    • Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin com-bination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
    • (2004) Ann Intern Med , vol.140 , pp. 346-55
    • Hadziyannis, S.J.1    Sette Jr., H.2    Morgan, T.R.3    Balan, V.4    Diago, M.5    Marcellin, P.6
  • 23
    • 0032547938 scopus 로고    scopus 로고
    • Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
    • McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
    • (1998) N Engl J Med , vol.339 , pp. 1485-92
    • McHutchison, J.G.1    Gordon, S.C.2    Schiff, E.R.3    Shiffman, M.L.4    Lee, W.M.5    Rustgi, V.K.6
  • 24
    • 2442683905 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previ-ously untreated patients infected with HCV genotypes 2 or 3
    • Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previ-ously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.
    • (2004) J Hepatol , vol.40 , pp. 993-9
    • Zeuzem, S.1    Hultcrantz, R.2    Bourliere, M.3    Goeser, T.4    Marcellin, P.5    Sanchez-Tapias, J.6
  • 25
    • 79955601866 scopus 로고    scopus 로고
    • United States life tables 2006
    • Arias E. United States life tables, 2006. Natl Vital Stat Rep 2010;58:1-40.
    • (2010) Natl Vital Stat Rep , vol.58 , pp. 1-40
    • Arias, E.1
  • 27
    • 0030720484 scopus 로고    scopus 로고
    • Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C
    • Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127: 855-65.
    • (1997) Ann Intern Med , vol.127 , pp. 855-65
    • Bennett, W.G.1    Inoue, Y.2    Beck, J.R.3    Wong, J.B.4    Pauker, S.G.5    Davis, G.L.6
  • 28
    • 0035700211 scopus 로고    scopus 로고
    • Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults
    • Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001;111:667-8.
    • (2001) Am J Med , vol.111 , pp. 667-8
    • Singer, M.E.1    Younossi, Z.M.2
  • 29
    • 0032583497 scopus 로고    scopus 로고
    • Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs
    • Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088-93.
    • (1998) JAMA , vol.280 , pp. 2088-93
    • Wong, J.B.1    Bennett, W.G.2    Koff, R.S.3    Pauker, S.G.4
  • 30
    • 0035120575 scopus 로고    scopus 로고
    • Assessment of utilities and health-related quality of life in patients with chronic liver disease
    • Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastro-enterol 2001;96:579-83.
    • (2001) Am J Gastro-enterol , vol.96 , pp. 579-83
    • Younossi, Z.M.1    Boparai, N.2    McCormick, M.3    Price, L.L.4    Guyatt, G.5
  • 32
    • 0037372609 scopus 로고    scopus 로고
    • Cost effectiveness of peginter-feron alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C
    • Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginter-feron alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-32.
    • (2003) Gut , vol.52 , pp. 425-32
    • Siebert, U.1    Sroczynski, G.2    Rossol, S.3    Wasem, J.4    Ravens-Sieberer, U.5    Kurth, B.M.6
  • 33
    • 0033056294 scopus 로고    scopus 로고
    • Efficacy of interferon alfacon-1 daily induction therapy followed by three-times weekly therapy in patients with chronic hepatitis C virus infection with high and low viral titers
    • Suzuki H, Iino S, Omata M, Kumada H, Hino K. Efficacy of interferon alfacon-1 daily induction therapy followed by three-times weekly therapy in patients with chronic hepatitis C virus infection with high and low viral titers. Hepatol Res 1999;15:64-79.
    • (1999) Hepatol Res , vol.15 , pp. 64-79
    • Suzuki, H.1    Iino, S.2    Omata, M.3    Kumada, H.4    Hino, K.5
  • 34
    • 0032585237 scopus 로고    scopus 로고
    • Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
    • Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352: 1426-32
    • (1998) Lancet , vol.352 , pp. 1426-32
    • Poynard, T.1    Marcellin, P.2    Lee, S.S.3    Niederau, C.4    Minuk, G.S.5    Ideo, G.6
  • 35
    • 0037564237 scopus 로고    scopus 로고
    • National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (10-12 June 2002)
    • National Institutes of Health Consensus Development Con-ference Statement: Management of hepatitis C 2002 (10-12 June 2002). Gastroenterology 2002;123:2082-99.
    • (2002) Gastroenterology , vol.123 , pp. 2082-99
  • 36
    • 0032547944 scopus 로고    scopus 로고
    • Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group
    • Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
    • (1998) N Engl J Med , vol.339 , pp. 1493-9
    • Davis, G.L.1    Esteban-Mur, R.2    Rustgi, V.3    Hoefs, J.4    Gordon, S.C.5    Trepo, C.6
  • 37
    • 33644804915 scopus 로고    scopus 로고
    • Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C
    • Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43:54-63.
    • (2006) Hepatology , vol.43 , pp. 54-63
    • Iwasaki, Y.1    Ikeda, H.2    Araki, Y.3    Osawa, T.4    Kita, K.5    Ando, M.6
  • 38
    • 0031041924 scopus 로고    scopus 로고
    • Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
    • Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
    • (1997) Gastroenterology , vol.112 , pp. 463-72
    • Fattovich, G.1    Giustina, G.2    Degos, F.3    Tremolada, F.4    Diodati, G.5    Almasio, P.6
  • 40
    • 1642484544 scopus 로고    scopus 로고
    • Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990
    • Krahn M, Wong JB, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making 2004;24:20-9.
    • (2004) Med Decis Making , vol.24 , pp. 20-9
    • Krahn, M.1    Wong, J.B.2    Heathcote, J.3    Scully, L.4    Seeff, L.5
  • 41
    • 0028275912 scopus 로고
    • Liver transplantation for hepatitis C virus-related cirrhosis
    • Ascher NL, Lake JR, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994;20:24S-27S.
    • (1994) Hepatology , vol.20
    • Ascher, N.L.1    Lake, J.R.2    Emond, J.3    Roberts, J.4
  • 43
    • 0027458066 scopus 로고
    • An analysis of liver transplant experience from 37 transplant centers as reported to Medicare
    • Kilpe VE, Krakauer H, Wren RE. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993;56:554-61.
    • (1993) Transplantation , vol.56 , pp. 554-61
    • Kilpe, V.E.1    Krakauer, H.2    Wren, R.E.3
  • 44
    • 3242750664 scopus 로고    scopus 로고
    • Survival after liver transplantation in the United States: A disease-specific analysis of the UNOS database
    • Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004;10:908-10.
    • (2004) Liver Transpl , vol.10 , pp. 908-10
    • Roberts, M.S.1    Angus, D.C.2    Bryce, C.L.3    Valenta, Z.4    Weissfeld, L.5
  • 46
    • 0027243462 scopus 로고
    • Risk factors for hepatocellular carcinoma among patients with chronic liver disease
    • Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;329:1896-7.
    • (1993) N Engl J Med , vol.329 , pp. 1896-7
    • Tsukuma, H.1    Hiyama, T.2    Tanaka, S.3    Nakao, M.4    Yabuuchi, T.5    Kitamura, T.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.